1. |
Yang WY, Lu JM, Weng JP, et al. Prevalence of diabetes among men and woman in China[J]. N Engl J Med, 2012, 362(2):1090-1101.
|
2. |
马学毅, 杨明功, 邓大同, 等. 现代糖尿病诊断治疗学[M]. 北京:人民军医出版社, 2007:68-197.
|
3. |
马艳芬, 刘薇, 袁明霞, 等. 胰岛素与口服降糖药对新诊断2型糖尿病患者β细胞功能的影响[J]. 中国糖尿病杂志, 2009, 17(5):349.
|
4. |
周映红, 黄文龙, 张惠斌, 等. GLP-1受体激动剂及DPP-4抑制剂的研究进展[J]. 中国药科大学学报, 2008, 39(5):385-391.
|
5. |
Bergman AJ, Cote J, Mase A, et al. Sitagliptin (MK-0431), a selective dipeptidyl-peptidase (DPP-4) inhibitor dose not affect the pharmacokinetics of simvastatin in humans[J]. Clin Pharmaol Ther, 2005, 79(2):48.
|
6. |
Basu AK, Bandyopadhyay D, Bandyopahyay R. Insulin in type 2 diabetes:promises to keep[J]. J Indian Med Assoc, 2004, 102(1):438-442.
|
7. |
Dailey G. New strategies for basal insulin treatment in type 2 diabetes mellitus[J]. Clin Ther, 2004, 263(11):889-901.
|
8. |
Gerich J, Becker RH, Zhu R, et al. Fluctuation of serum basal insulin levels following single and multiple dosing of insulin glarging[J]. Diabetes Technol Ther, 2006, 8(2):237-243.
|
9. |
潘宇平, 郑启东, 陈婉, 等. 西格列汀联合二甲双胍治疗2型糖尿病临床观察[J]. 中国乡村医学, 2013, 6(1):21-22.
|
10. |
Nonaka K, kakikawa T, Sato A, et al. Efficacy and safety of sitaglipt in monotherapy in Japanese patients with type 2 diabetes[J]. Diabetes Res Clin Pract, 2008, 79(4):291-298.
|
11. |
Fonseca V, Schweizer A, Albrecht D, et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes[J]. Diabetologia, 2007, 50(3):1148-1155.
|
12. |
陈卓, 张庆文. DPP-4抑制剂研究进展[J]. 上海医药, 2013, 7(1):50-54.
|
13. |
曾丽丽, 丁英杰, 宋宏锐, 等. 二肽基肽酶-Ⅳ抑制剂的最新研究进展[J].中国药物化学杂志, 2009, 19(1):65-70.
|
14. |
Herman G, Hanefeld M, Wu M, et al. Effect of MK-0431, a dipeptidyl peptidase Ⅳ(DPPⅣ) inhibitor on glycaemic control after 12 weeks in patients with type 2 diabetes[J]. Diabetes, 2005, 54(Suppl 1):A134, 541.
|
15. |
Hansen AM, Hansen JB, Car RD, et al. Kir62 dependent high-affinity repaglinide binding to betacell K (ATP) channels[J]. Br J Pharmacol, 2005, 144(4):551-557.
|
16. |
廖二元, 莫朝晖. 内分泌学[M]. 北京:人民卫生出版社, 2007:1395.
|